SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001493152-21-013659
Filing Date
2021-06-04
Accepted
2021-06-04 17:24:49
Documents
8
Period of Report
2021-06-04

Document Format Files

Seq Description Document Type Size
1 form6-k.htm 6-K 32456
2 ex4-1.htm EX-4.1 112135
3 ex4-2.htm EX-4.2 111152
4 ex4-3.htm EX-4.3 137424
5 ex10-1.htm EX-10.1 305093
6 ex10-2.htm EX-10.2 120306
7 ex10-3.htm EX-10.3 184759
8 ex99-1.htm EX-99.1 14351
  Complete submission text file 0001493152-21-013659.txt   1018807
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 6-K | Act: 34 | File No.: 001-40101 | Film No.: 21997504
SIC: 2834 Pharmaceutical Preparations